| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Revakinagene taroretcel | NT-501 | Approved | Gnt Pharma | ENCELTO, Encelto | United States | Macular telangiectasia 2 | Gnt Pharma | 2025-03-05 | Color Vision Defects; Eye Diseases; Glaucoma; Macular telangiectasia 2; Retinitis Pigmentosa; Telangiectasis; Usher Syndromes | Details |